Relative versus attributable risk of breast cancer from estrogen replacement therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 6, 1999, Pages 1875-1881

  Santen, Richard J ^a   Petroni, Gina R ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSE; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UTERUS CANCER;

EID: 0033305318     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.6.5771     Document Type: Note

References (42)

1. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women
2. Benefits of hormone replacement therapy-overview and update
3. Hormone replacement therapy and its potential relationship to dementia
4. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
5. Estrogen replacement and fractures in older women
6. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
7. Myocardial infarction and the use of estrogen and estrogen-progestogen in post-menopausal women
8. Postmenopausal hormone use and risk of large bowel cancer
9. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease
10. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease
11. Estrogen, cognition and a Woman's risk of Alzheimer's disease
12. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia
13. Postmenopausal hormone therapy and mortality
14. Use of menopausal estrogens and medroxyprogesterone acetate in the United States
15. Use of estrogens among middle aged Massachusetts women
16. Duration/dose of HRT and risk of breast cancer in unselected populations: Data from meta-analysis
17. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
18. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
19. Adenocarcinoma of the vagina: Association of maternal stilbestrol therapy with tumor appearance in young women
20. Vaginal cancer after maternal treatment with synthetic estrogens
21. Diethylstlbestrol exposure and the risk of clear cell cervical and vaginal adenocarcinoma
22. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108411 women without breast cancer
23. Androgen and estrogen metabolism: Relationship to obesity
24. Cancer statistics 1996
25. Trade-off strategy for assessing willingness of breast cancer patients to accept HRT
26. Hormone therapy to prevent disease and prolong life in postmenopausal women
27. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women
28. Risk of venous thrombosis with hormone replacement therapy
29. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
30. Patient-specific decisions about hormone replacement therapy in postmenopausal women
31. Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk
32. Prevention of heart disease: The role of estrogens and SERMs
33. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
34. Alternatives to the use of estrogen in postmenopausal women
35. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestin replacement therapy
36. The relationship between breast cancer survival and prior postmenopausal estrogen use
37. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy
38. Effect of progestins as mammary mitogens
39. The risk of breast cancer after estrogen and estrogen-progestin replacement